Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab

Journal of Nephrology

Volumn 30, Issue 3, 2017, Pages 347-362

  Asif, Arif ^a   Nayer, Ali ^b   Haas, Christian S ^c  

^a JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Complement; Hypertension; Kidney transplantation; Pregnancy; Thrombotic microangiopathy

Indexed keywords

ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; ECULIZUMAB; MENINGOCOCCUS VACCINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; COMPLEMENT; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ARTERIOLOSCLEROSIS; BLEEDING; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FETUS DEATH; GRAFT REJECTION; HEADACHE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION RETINOPATHY; HYSTERECTOMY; IMMUNOADSORPTION; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TUBULE DAMAGE; MALIGNANT HYPERTENSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPILLEDEMA; PLASMA EXCHANGE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; REVIEW; SOLUTIO PLACENTAE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINE VOLUME; VISUAL IMPAIRMENT; ALGORITHM; CLINICAL DECISION MAKING; COMORBIDITY; COMPLEMENT ACTIVATION; DECISION SUPPORT SYSTEM; DRUG EFFECTS; IMMUNOLOGY; PREDICTIVE VALUE; PREGNANCY; PREGNANCY COMPLICATION; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ALGORITHMS; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CLINICAL DECISION-MAKING; COMORBIDITY; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 85019638219     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-016-0357-7     Document Type: Review

References (108)

1. George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654–666
2. Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589–600
3. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676–1687
4. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554–562
5. Campistol JM, Arias M, Ariceta G et al (2015) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 35:421–447
6. Nayer A, Asif A (2016) Atypical hemolytic-uremic syndrome: a clinical review. Am J Ther 23:e151–e158
7. Neuhaus TJ, Calonder S, Leumann EP (1997) Heterogeneity of atypical haemolytic uraemic syndromes. Arch Dis Child 76:518–521
8. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392–2400
9. Noris M, Caprioli J, Bresin E et al (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859
10. Geerdink LM, Westra D, van Wijk JA et al (2012) Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 27:1283–1291
11. Ariceta G, Besbas N, Johnson S et al (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687–696
12. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T (2010) Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 36:673–681
13. US Food and Drug Administration (2015) Soliris (eculizumab) [prescribing information]. Alexion Pharmaceuticals, Inc., Cheshire, CT
14. European Medicines Agency (2015) Soliris (eculizumab) [summary of product characteristics]. Alexion Europe SAS, Paris
15. Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181
16. Licht C, Greenbaum LA, Muus P et al (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061–1073
17. Greenbaum LA, Fila M, Ardissino G et al (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701–711
18. Fakhouri F, Hourmant M, Campistol JM et al (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84–93
19. Riedl M, Fakhouri F, Le Quintrec M et al (2014) Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40:444–464
20. Kavanagh D, Goodship THJ, Richards A (2006) Atypical haemolytic uraemic syndrome. Br Med Bull 77 and 78:5–22
21. Akimoto T, Muto S, Ito C et al (2011) Clinical features of malignant hypertension with thrombotic microangiopathy. Clin Exp Hypertens 33:77–83
22. Barbour T, Johnson S, Cohney S, Hughes P (2012) Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant 27:2673–2685
23. Nester CM, Thomas CP (2012) Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program 2012:617–625
24. Noris M, Mescia F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8:622–633
25. Kavanagh D, Goodship TH, Richards A (2013) Atypical hemolytic uremic syndrome. Semin Nephrol 33:508–530
26. Khanal N, Dahal S, Upadhyay S, Bhatt VR, Bierman PJ (2015) Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. Ther Adv Hematol 6:97–102
27. Dashe JS, Ramin SM, Cunningham FG (1998) The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy. Obstet Gynecol 91:662–668
28. Fakhouri F, Roumenina L, Provot F et al (2010) Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21e:859–867
29. Vaught AJ, Gavriilaki E, Hueppchen N et al (2016) Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome. Exp Hematol 44:390–398
30. Shrivastava M, Modi G, Singh RK, Navaid S (2011) Early diagnosis and management of postpartum hemolytic uremic syndrome with plasma exchange. Transfus Apher Sci 44:257–262
31. Mu J, Zhang J, Sunnassee A, Dong H (2015) A case report of undiagnosed postpartum hemolytic uremic syndrome. Diagn Pathol 10:89
32. Calvert GD (1972) Postpartum haemolytic uraemic syndrome: case report and brief review. J Obstet Gynaecol Br Commonw 79:244–249
33. Delmas Y, Bordes C, Loirat C, Fremeaux-Bacchi V, Combe C (2013) Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. Clin Kidney J 6:243–244
34. Ardissino G, Wally Ossola M, Baffero GM, Rigotti A, Cugno M (2013) Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 122:487–489
35. Carr R, Cataland SR (2013) Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. Ann Hematol 92:845–846
36. Zschiedrich S, Prager EP, Kuehn EW (2013) Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab. Ann Intern Med 159:76
37. Canigral C, Moscardo F, Castro C et al (2014) Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Ann Hematol 93:1421–1422
38. Mussoni MP, Veneziano FA, Boetti L, et al. (2014) Innovative therapeutic approach: sequential treatment with plasma exchange and eculizumab in a pregnant woman affected by atypical hemolytic-uremic syndrome. Transfus Apher Sci 51:134–136
39. De Sousa Amorim E, Blasco M, Quintana L, Sole M, de Cordoba SR, Campistol JM (2015) Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management. J Nephrol 28:641–645
40. Saad AF, Roman J, Wyble A, Pacheco LD (2016) Pregnancy-associated atypical hemolytic-uremic syndrome. AJP Rep 6:e125–128
41. Tsai HM, Kuo E (2016) From gestational hypertension and preeclampsia to atypical hemolytic uremic syndrome. Obstet Gynecol 127:907–910
42. Kelly RJ, Hochsmann B, Szer J et al (2015) Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 373:1032–1039
43. Hallstensen RF, Bergseth G, Foss S et al (2015) Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology 220:452–459
44. Miyasaka N, Miura O, Kawaguchi T et al (2016) Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol 103:703–712
45. Shibagaki Y, Fujita T (2005) Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other? Hypertens Res 28:89–95
46. van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA (2005) Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension 45:246–251
47. Mathew RO, Nayer A, Asif A (2016) The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. J Am Soc Hypertens 10:352–359
48. Kincaid-Smith P (1982) Renal pathology in hypertension and the effects of treatment. Br J Clin Pharmacol 13:107–115
49. Farquharson CA, Struthers AD (2002) Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 103:425–431
50. Cachofeiro V, Miana M, de Las Heras N et al (2008) Aldosterone and the vascular system. J Steroid Biochem Mol Biol 109:331–335
51. van den Born BJH, Lowenberg EC, van der Hoeven NV et al (2011) Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens 29:922–927
52. Tsai HM (2016) Does anticomplement therapy have a role in the management of malignant hypertension? J Clin Hypertens (Greenwich) 18:359–360
53. Totina A, Iorember F, El-Dahr SS, Yosypiv IV (2013) Atypical hemolytic-uremic syndrome in a child presenting with malignant hypertension. Clin Pediatr (Phila) 52:183–186
54. Rafiq A, Tariq H, Abbas N, Shenoy R (2015) Atypical hemolytic-uremic syndrome: a case report and literature review. Am J Case Rep 16:109–114
55. Zhang B, Xing C, Yu X, Sun B, Zhao X, Qian J (2008) Renal thrombotic microangiopathies induced by severe hypertension. Hypertens Res 31:479–483
56. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C (2011) Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 26:613–619
57. Garjau M, Azancot M, Ramos R, Sanchez-Corral P, Montero MA, Seron D (2012) Early treatment with eculizumab in atypical haemolytic uraemic syndrome. Clin Kidney J 5:31–33
58. Besbas N, Gulhan B, Karpman D et al (2013) Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 28:155–158
59. Sajan T, Vinay S, Sonu N, Alan P (2014) How atypical can atypical hemolytic uremic syndrome be? Clin Case Rep 2:57–59
60. Ohta T, Urayama K, Tada Y et al (2015) Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension. Pediatr Nephrol 30:603–608
61. Sevinc M, Basturk T, Sahutoglu T et al (2015) Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report. J Med Case Rep 9:92
62. Sharma S, Pradhan M, Meyers KE, Le Palma K, Laskin BL (2015) Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab. Clin Nephrol 84:181–185
63. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643–657
64. Le Quintrec M, Zuber J, Moulin B et al (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13:663–675
65. Zuber J, Le Quintrec M, Krid S et al (2012) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12:3337–3354
66. Ornstein BW, Atkinson JP, Densen P (2012) The complement system in pediatric systemic lupus erythematosus, atypical hemolytic uremic syndrome, and complocentric membranoglomerulopathies. Curr Opin Rheumatol 24:522–529
67. Leffler J, Bengtsson AA, Blom AM (2014) The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis 73:1601–1606
68. Birmingham DJ, Hebert LA (2015) The complement system in lupus nephritis. Semin Nephrol 35:444–454
69. Zhao J, Wu H, Khosravi M et al (2011) Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 7:e1002079
70. Jonsen A, Nilsson SC, Ahlqvist E et al (2011) Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Res Ther 13:R206
71. Chen MH, Chen MH, Chen WS et al (2011) Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology (Oxford) 50:768–775
72. Bridoux F, Vrtovsnik F, Noel C et al (1998) Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dial Transplant 13:298–304
73. Song D, Wu LH, Wang FM et al (2013) The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 15:R12
74. Musio F, Bohen EM, Yuan CM, Welch PG (1998) Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 28:1–19
75. Banfi G, Bertani T, Boeri V et al (1991) Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 18:240–248
76. Jain R, Chartash E, Susin M, Furie R (1994) Systemic lupus erythematosus complicated by thrombotic microangiopathy. Semin Arthritis Rheum 24:173–182
77. Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG (2006) Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis 65:144–148
78. Samson M, Audia S, Leguy V et al (2012) Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange. Intern Med J 42:95–98
79. Coppo R, Peruzzi L, Amore A et al (2015) Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 30:167–172
80. El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP (2015) Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 65:127–130
81. Ramachandran R, Sakhuja V, Jha V, Kohli HS, Rathi M (2012) Plasmapheresis in systemic lupus erythematosus with thrombotic microangiopathy. Intern Med J 42:734
82. Gharbi C, Bourry E, Rouvier P et al (2010) Rapidly progressive lupus nephritis and concomitant thrombotic microangiopathy. Clin Exp Nephrol 14:487–491
83. Hadaya K, Ferrari-Lacraz S, Fumeaux D et al (2011) Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 11:2523–2527
84. Stratta P, Besso L, Ferrero S et al (1996) Scleroderma renal crisis is still a life-threatening syndrome. Ren Fail 18:567–574
85. Zwettler U, Andrassy K, Waldherr R, Ritz E (1993) Scleroderma renal crisis as a presenting feature in the absence of skin involvement. Am J Kidney Dis 22:53–56
86. Yamanaka K, Mizutani H, Hashimoto K, Nishii M, Shimizu M (1997) Scleroderma renal crisis complicated by hemolytic uremic syndrome in a case of elderly onset systemic sclerosis. J Dermatol 24:184–188
87. Ricker DM, Sharma HM, Nahman NS Jr (1989) Acute renal failure with glomerular thrombosis in a patient with chronic scleroderma. Am J Kidney Dis 14:524–526
88. Meyrier A, Becquemont L, Weill B, Callard P, Rainfray M (1991) Hemolytic-uremic syndrome with anticardiolipin antibodies revealing paraneoplastic systemic scleroderma. Nephron 59:493–496
89. Haviv YS, Safadi R (1998) Normotensive scleroderma renal crisis: case report and review of the literature. Ren Fail 20:733–736
90. Chen WS, Young AH, Wang HP, Huang DF (2009) Hemolytic uremic syndrome with ischemic glomerulonephropathy and obliterative vasculopathy in a systemic sclerosis patient treated with cyclosporine-A. Rheumatol Int 29:821–824
91. Thomas CP, Nester CM, Phan AC, Sharma M, Steele AL, Lenert PS (2015) Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome. Clin Kidney J 8:698–701
92. Craner GE, Burdick GE (1976) Acute colitis resembling ulcerative colitis in the hemolytic-uremic syndrome. Am J Dig Dis 21:74–76
93. Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hallgren R (1990) Enhanced local production of complement components in the small intestines of patients with Crohn’s disease. N Engl J Med 322:1345–1349
94. Sugihara T, Kobori A, Imaeda H et al (2010) The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol 160:386–393
95. Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P (1992) Surface epithelium related activation of complement differs in Crohn’s disease and ulcerative colitis. Gut 33:902–908
96. Green H, Harari E, Davidovits M et al (2014) Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren Fail 36:1119–1121
97. Webb TN, Griffiths H, Miyashita Y et al (2015) Atypical hemolytic uremic syndrome and chronic ulcerative colitis treated with eculizumab. Int J Med Pharm Case Reports 4:105–112
98. Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN (2015) Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 125:616–618
99. Reese JA, Bougie DW, Curtis BR et al (2015) Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the BloodCenter of Wisconsin. Am J Hematol 90:406–410
100. Izzedine H, Perazella MA (2015) Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 66:857–868
101. Blake-Haskins JA, Lechleider RJ, Kreitman RJ (2011) Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 17:5858–5866
102. Pisoni R, Ruggenenti P, Remuzzi G (2001) Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf 24:491–501
103. Faguer S, Huart A, Fremeaux-Bacchi V, Ribes D, Chaveau D (2013) Eculizumab and drug-induced haemolytic-uraemic syndrome. Clin Kidney J 6:484–485
104. Safa K, Logan MS, Batal I, Gabardi S, Rennke HG, Abdi R (2015) Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report. Clin Nephrol 83:125–129
105. Nurnberger J, Philipp T, Witzke O et al (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360:542–544
106. Starck M, Wendtner CM (2014) Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy. Br J Haematol 164:894–896
107. Noris M, Remuzzi G (2013) Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 22:704–712
108. Loirat C, Fakhouri F, Ariceta G et al (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15–39